Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Feb;9(2):219-21.
doi: 10.2215/CJN.12411213. Epub 2014 Jan 9.

Serum potassium in dual renin-angiotensin-aldosterone system blockade

Stephen L Seliger  1 , Linda F Fried
Affiliations
Editorial

Serum potassium in dual renin-angiotensin-aldosterone system blockade

Stephen L Seliger et al. Clin J Am Soc Nephrol. 2014 Feb.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869, 2001 - PubMed
    1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–1462, 1993 - PubMed
    1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860, 2001 - PubMed
    1. de Zeeuw D: Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 66: S2–S6, 2004 - PubMed
    1. Tobe SW, Dai MO: Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy. Curr Hypertens Rep 11: 345–353, 2009 - PubMed

MeSH terms